Motley Fool Wealth Management LLC Has $24 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Motley Fool Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 63.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 53,913 shares of the pharmaceutical company’s stock after purchasing an additional 20,864 shares during the period. Vertex Pharmaceuticals accounts for 1.4% of Motley Fool Wealth Management LLC’s holdings, making the stock its 19th biggest position. Motley Fool Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $24,002,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals in the 1st quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 45 shares in the last quarter. Flaharty Asset Management LLC acquired a new position in Vertex Pharmaceuticals in the 1st quarter valued at $32,000. American National Bank & Trust grew its holdings in Vertex Pharmaceuticals by 515.4% in the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 67 shares in the last quarter. Finally, Solstein Capital LLC acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $40,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.3%

VRTX stock opened at $420.17 on Tuesday. The stock has a market capitalization of $107.73 billion, a P/E ratio of 30.03 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a 50-day moving average price of $399.56 and a 200-day moving average price of $433.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Evercore ISI decreased their price objective on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a report on Thursday, September 11th. Raymond James Financial began coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a “market perform” rating on the stock. Morgan Stanley reduced their target price on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Leerink Partners raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their target price for the stock from $458.00 to $456.00 in a report on Thursday, September 25th. Finally, Wells Fargo & Company raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.